Overall rank by patents
#4,211
of 49,997 tracked assignees
USPTO PatentsView assignee record - 85 granted patents across 81 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: D07B (Ropes OR Cables IN General).
The verdict
According to USPTO PatentsView, NV ranks #4,211 of 49,997 tracked US assignees by granted-patent volume, with 85 patents across 81 technology areas.
USPTO PatentsView assignee plate
Corpus R4211 · Foreign Corporation #4,211 · 85 grants
GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL
Nearest grant-volume peer: Levi Strauss & Co. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Bekaert · this assignee
54 score
Inari Medical · near
54 score
National University… · near
54 score
University of… · near
54 score
Novamont S p A · near
54 score
3D Lighting… · lowest
7 score
What this shows NV's Innovation Score is 53.5/100 (top 9% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Between 2020–2024, NV Bekaert SA received 30 grants versus 49 in 2015–2019 (-39% equal-window velocity, below median growth). Across complete PatentsView years, output peaked in 2018 at 11 grants and bottomed in 2021 at 4. Lead class D07B accounts for 28.2% of the portfolio across 81 subclasses. Volume neighbours: Levi Strauss & Co. (#4,206) and Omrix Biopharmaceuticals Ltd. (#4,214).
From 2019–2021 to 2022–2024, NV Bekaert SA moved from 23 to 17 grants (0.74x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Levi Strauss & Co.
85 patents
MTG Co., Ltd.
85 patents
Macrogenics, Inc.
85 patents
Nifco Korea Inc.
85 patents
Nobel Biocare Services AG
85 patents
O&M Halyard, Inc.
85 patents
Océ Holding B.V.
85 patents
Omrix Biopharmaceuticals Ltd.
85 patents
NV Bekaert SA
85 patents
What this shows NV holds 85 patents at rank #4,210, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #4,210 in granted patent volume.
Other assignees with the most granted patents in NV's primary technology class.
Two PlainPatent-derived peer sets for NV, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (54 here).
Nearest assignees by average claims per patent (13.7 here).
NV's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
54 Top 9% higher than 91% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 10 | 11.8% |
| 2016 | 10 | 11.8% |
| 2017 | 8 | 9.4% |
| 2018 | 11 | 12.9% |
| 2019 | 10 | 11.8% |
| 2020 | 9 | 10.6% |
| 2021 | 4 | 4.7% |
| 2022 | 8 | 9.4% |
| 2023 | 5 | 5.9% |
| 2024 | 4 | 4.7% |
| 2025partial year | 6 | 7.1% |
Top 15 of 81 technology areas
Overall rank by patents
#4,211
of 49,997 tracked assignees
53.5 out of 100
What to do with this data
NV Bekaert SA's patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.